Bob Löwenberg - Biography#

Bob Löwenberg is Professor of Hematology at Erasmus University in Rotterdam, the Netherlands and past scientific director of the Rotterdam Cancer Center “Daniel den Hoed”.

Between 2013-2020 he served as the first non-US Editor-in-Chief of "Blood" (Washington, DC), one of the leading international scientific biomedical journals, with a focus on blood and blood diseases.

Professor Löwenberg’s research activities at Erasmus University Medical Center Rotterdam focus on the abnormal biological features of leukemia, and their potential diagnostic and treatment utility. Through his role in international multicenter prospective phase I-II and phase III clinical trials in leukemia he has been actively engaged in developmental therapeutics with particular consideration of the molecular heterogeneity of the disease and advancing new treatment concepts. The large phase III studies are embedded in the European HOVON Cooperative Group Network. He has published extensively in leading scientific journals.

Bob Löwenberg has held various leading positions. Professor Löwenberg was one of the founding fathers and has served as President of the European Haematology Association (EHA). He has also been president of the International Society of Experimental Hematology and the International Society of Hematology. He is immediate past Chairman of the Scientific Advisory Board and current Vice-President of the Board of the European School of Hematology (Paris). He founded and served as the first president of the Dutch-Belgian Cooperative Group on Hemato-Oncology in Adults (HOVON Cooperative Group), one of the leading cooperative consortia, which runs clinical trials in hemato-oncology in Europe. He is one of the original three founders of the biotech start-up Crucell, (1994, Leiden, NL) now part of Johnson & Johnson and one of the three founders of the cancer immunotherapy company Frame Therapeutics (2019, Amsterdam).

Bob Löwenberg has received various honors for his contributions to the field of hematology (section 1.14) . He is an elected member of the Royal Academy of Sciences and Arts of The Netherlands. In 2011 he was honored by the Dutch Queen: Knight of the Royal Order of the Netherlands Lion.